Effects of chronic fluoxetine treatment on catalepsy and the immune response in mice with a genetic predisposition to freezing reactions: The roles of types 1A and 2A serotonin receptors and the tph2 and SERT genes

Neuroscience and Behavioral Physiology

Volumn 40, Issue 5, 2010, Pages 521-527

  Tikhonova, M A ^a   Alperina, E L ^b   Tolstikova, T G ^c   Bazovkina, D V ^a   Di, V Yu ^a   Idova, G V ^b   Kulikov, A V ^a   Popova, N K ^a  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^b ENERGY SYSTEMS INSTITUTE   (Russian Federation)

^c N N VOROZHTSOV NOVOSIBIRSK INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

Author keywords

5 HT 2A receptors; 5 HT1A receptors; Catalepsy; Depression like state; Fluoxetine; Immune response; Serotonin transporter; Tryptophan hydroxylase 2

Indexed keywords

FLUOXETINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE 2;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG RESPONSE; FRONTAL CORTEX; GENE EXPRESSION; GENETIC PREDISPOSITION; IMMUNE RESPONSE; MALE; MESENCEPHALON; MOUSE; NONHUMAN; SEROTONINERGIC SYSTEM; SPLEEN;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CATALEPSY; FLUOXETINE; GENETIC PREDISPOSITION TO DISEASE; MALE; MICE; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; ROSETTE FORMATION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SPECIES SPECIFICITY; TRYPTOPHAN HYDROXYLASE;

EID: 77955541232     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-010-9291-7     Document Type: Article

References (30)

1. E. L. Alperina, A. V. Kulikov, N. K. Popova, and G. V. Idova, "The nature of the immune response in mice of the new strain ASC (Antidepressant Sensitive Catalepsy)," Byull. Eksperim. Biol. Med., 144, No.8, 188-190 (2007).
2. D. V. Bazovkina, A. V. Kulikov, E. M. Kondaurova, and N. K. Popova, "Breeding for a predisposition to catalepsy increases depression-like behavior in mice," Genetika, 41, No.9, 1222-1228 (2005).
3. A. V. Kulikov, "Inherited catalepsy. The genetic-molecular mechanisms of catalepsy in mice," Genetika, 40, No.6, 779-786 (2004).
4. S. V. Magaeva, "The role of brain limbic structures in regulating immunological reactions," in: Immunophysiology [in Russian], E. A. Korneva (ed.), Nauka, St. Petersburg (1993), pp. 137-148.
5. V. S. Naumenko and A. V. Kulikov, "Assay of the expression of the 5-HT1A serotonin receptor in the brain," Mol. Biol., 40, No.1, 37-44 (2006).
6. N. G. Panteleeva, N. I. Gryazeva, L. V. Verbitskaya, A. V. Shurlygina, V. A. Trufakin,V. G. Kolpakov, T. A. Alekhina, and N. N. Barykina, "Comparative analysis of the daily dynamics of the sub-population composition of lymphocytes in the lymphoid organs in rights with a genetic catalepsy and in Wistar rats," Byull. Eksperim. Biol. Med., 137, No.3, 325-327 (2004).
7. M. A. Tikhonova,V. V. Lebedeva, A. V. Kulikov, D. V. Bazovkina, and N. K. Popova, "Effects of imipramine on behavior and brain 5-HT1A serotonin receptors in mice with a genetic predisposition to freezing reactions," Byull. Eksperim. Biol. Med., 141, No.1, 53-55 (2006).
8. S. Benmansour, M. Checchi, D. Morilak, G. Gerhardt, M. A. Javors, G. G. Gould, and A. Frazer, "Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level," J. Neurosci., 19, No.23, 10494-10501 (1999).
9. P. Blier and C. De Montigny, "Current advances and trends in the treatment of depression," Trends Pharmacol. Sci., 15, 220-226 (1994).
10. M. O. Butler, S. Morinobu, and R. S. Duman, "Chronic electroconvulsive seizures increase the expression of serotonin2 receptor mRNA in rat frontal cortex," J. Neurochem., 61, No.4, 1270-1276 (1993).
11. L. Devoino, E. Alperina, E. Podgornaya, R. Ilyutchenok, G. Idova, and O. Polyakov, "Regional changes of brain serotonin and its metabolite 5-hydroxyindolacetic acid and development of immunosuppression in submissive mice," Int. J. Neurosci., 114, No.9, 1049-1062 (2004).
12. L. Devoino, G. Idova, E. Alperina, and M. Cheido, "Brain neuromediator systems in the immune response control: pharmacological analysis of pre-and postsynaptic mechanisms," Brain Res., 633, 267-274 (1994).
13. A. J. Dunn, "Effects of cytokines and infections on brain neurochemistry," Clin. Neurosci. Res., 6, No.1-2, 52-68 (2006).
14. E. M. Friedman, K. A. Becker, D. H. Overstreet, and D. A. Lawrence, "Reduced primary antibody responses in a genetic animal model of depression," Psychosom. Med., 64, No.2, 267-273 (2002).
15. A. R. Green and D. J. Heal, "The effects of drugs on serotonin-mediated behavioural models," in: Neuropharmacology of Serotonin, A. R. Green (ed.), Oxford University Press, Oxford (1985), pp. 326-365.
16. G. V. Idova, S. M. Davydova, M. A. Cheido, E. N. Zhukova, and L. V. Devoino, "Significance of initial emotional state for neuroimmunomodulation in conditions of activation and blockade of 5-HT(lA) receptors," Neurosci. Behav. Physiol., 36, No.7, 703-707 (2006).
17. A. V. Kulikov, D. V. Bazovkina, E. M. Kondaurova, and N. K. Popova, "Genetic structure of hereditary catalepsy in mice," Genes Brain Behav., 7, No.4, 506-512 (2008).
18. A. V. Kulikov, V. G. Kolpakov, and N. K. Popova, "The genetic cataleptic (GC) rat strain as a model of depressive disorders," in: Animal Models in Biological Psychiatry, A. N. Kaluev (ed.), Nova Sci. Publ., New York (2006), pp. 59-73.
19. A. V. Kulikov, C. S. Naumenko, I. P. Voronova, M. A. Tikhonova, and N. K. Popova, "Quantitative RT-PCR assay of 5-HT1A and 5-HT2A serotonin receptor mRNAs using genomic DNA as an external standard," J. Neurosci. Meth., 141, No.1, 97-101 (2005).
20. A. V. Kulikov, M. A. Tikhonova, and V. A. Kulikov, "Automated measurement of spatial preference in the open field test with transmitted lighting," J. Neurosci. Meth., 170, No.2, 345-351 (2008).
21. M. Maes and H. Y. Meltzer, "The serotonin hypothesis of major depression," in: Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer (eds.), Raven Press, New York (1995), pp. 933-944.
22. J. Maj and E. Moryl, "Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists," Eur. Neuropsychophamacol., 3, No.2, 85-94 (1993).
23. K. F. Martin, I. Phillips, M. Hearson, M. R. Prow, and D. J. Heal, "Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants," Br. J. Pharmacol., 107, No.1, 15-21 (1992).
24. D. L. Murphy, A. Lerner, G. Rudnick, and K. P. Lesch, "Serotonin transporter: gene, genetic disorders, and pharmacogenetics," Mol. Interv., 4, No.2, 109-123 (2004).
25. J. P. Olie, E. Costa, J. Silva, and J. P. Macher, Neuroplasticity: A New Approach to the Pathophysiology of Depression, Sci. Press, London (2004).
26. D. R. Thakker, F. Natt, D. Husken, H. Van Der Putten, R. Maier, D. Hoyer, and J. F. Cryan, "siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain," Mol. Psychiatry, 10, No.8, 782-789 (2005). (Pubitemid 41129051)
27. D. J. Walther, J. U. Peter, S. Bashammakh, H. Hortnagl, M. Voits, H. Fink, and M. Bader, "Synthesis of serotonin by a second tryptophan hydroxylase isoform," Science, 299, 76 (2003).
28. P. Willner, "Animal models of depression: an overview," Pharmacol. Ther., 45, 425-455 (1990).
29. X. Zhang, J. M. Beaulieu, T. D. Sotnikova, R. R. Gainetdinov, and M. G. Caron, "Tryptophan hydroxylase-2 controls brain serotonin synthesis," Science, 305, 217 (2004).
30. X. Zhang, R. R. Gainetdinov, I. M. Beaulieu, T. D. Sotnikova, L. H. Burch, R. B. Williams, D. A. Schwartz, K. R. Krishnan, and M. G. Caron, "Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression," Neuron, 45, 11-16 (2005).